Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 5/2020

01-10-2020 | Gastroesophageal Reflux Disease | Case Report

Development of pseudoachalasia following magnetic sphincter augmentation (MSA) with restoration of peristalsis after endoscopic dilation

Authors: Katrin Schwameis, Shahin Ayazi, Ali H. Zaidi, Toshitaka Hoppo, Blair A. Jobe

Published in: Clinical Journal of Gastroenterology | Issue 5/2020

Login to get access

Abstract

Pseudoachalasia is mimicking clinical and physiologic manifestations of idiopathic achalasia but results from alternative etiologies that infiltrate or obstruct the esophagogastric junction (EGJ). Anti-reflux surgery is one of the potential etiologies of pseudoachalasia. The majority of cases with persistent dysphagia after a tightly constructed Nissen fundoplication results from EGJ outlet obstruction (EGJOO) and in rare cases progresses to pseudoachalasia. In these extreme cases, endoscopic dilation is not a sufficient treatment and take down of fundoplication would be necessary. In this case report, we present a patient with long-standing GERD symptoms that underwent magnetic sphincter augmentation (MSA) with complete resolution of his reflux symptoms. He did not have dysphagia prior to surgery and his preoperative manometry showed normal peristaltic progression of esophageal contractions. He developed pseudoachalasia 14 months after surgery. Repeated endoscopic dilation in this case resulted in resolution of dysphagia and complete restoration of peristaltic contractions.
Literature
1.
go back to reference Kahrilas PJ, Kishk SM, Helm JF, Dodds WJ, Harig JM, Hogan WJ. Comparison of pseudoachalasia and achalasia. Am J Med. 1987;82(3):439–46.CrossRef Kahrilas PJ, Kishk SM, Helm JF, Dodds WJ, Harig JM, Hogan WJ. Comparison of pseudoachalasia and achalasia. Am J Med. 1987;82(3):439–46.CrossRef
2.
go back to reference Fabian E, Eherer AJ, Lackner C, Urban C, Smolle-Juettner FM, Krejs GJ. Pseudoachalasia as first manifestation of a malignancy. Dig Dis. 2019;37(5):347–54.CrossRef Fabian E, Eherer AJ, Lackner C, Urban C, Smolle-Juettner FM, Krejs GJ. Pseudoachalasia as first manifestation of a malignancy. Dig Dis. 2019;37(5):347–54.CrossRef
3.
go back to reference Kim HM, Chu JM, Kim WH, Hong SP, Hahm KB, Ko KH. Extragastroesophageal malignancy-associated secondary achalasia: a rare association of pancreatic cancer rendering alarm manifestation. Clin Endosc. 2015;48(4):328–31.CrossRef Kim HM, Chu JM, Kim WH, Hong SP, Hahm KB, Ko KH. Extragastroesophageal malignancy-associated secondary achalasia: a rare association of pancreatic cancer rendering alarm manifestation. Clin Endosc. 2015;48(4):328–31.CrossRef
4.
go back to reference Scherer JR, Kwiatek MA, Soper NJ, Pandolfino JE, Kahrilas PJ. Functional esophagogastric junction obstruction with intact peristalsis: a heterogeneous syndrome sometimes akin to achalasia. J Gastroint Surg. 2009;13(12):2219–25.CrossRef Scherer JR, Kwiatek MA, Soper NJ, Pandolfino JE, Kahrilas PJ. Functional esophagogastric junction obstruction with intact peristalsis: a heterogeneous syndrome sometimes akin to achalasia. J Gastroint Surg. 2009;13(12):2219–25.CrossRef
5.
go back to reference Wilshire CL, Niebisch S, Watson TJ, et al. Dysphagia postfundoplication: more commonly hiatal outflow resistance than poor esophageal body motility. Surgery. 2012;152(4):584–92.CrossRef Wilshire CL, Niebisch S, Watson TJ, et al. Dysphagia postfundoplication: more commonly hiatal outflow resistance than poor esophageal body motility. Surgery. 2012;152(4):584–92.CrossRef
6.
go back to reference Ayazi S, DeMeester SR, Hagen JA, et al. Clinical significance of esophageal outflow resistance imposed by a nissen fundoplication. J Am Coll Surg. 2019;229(2):210–6.CrossRef Ayazi S, DeMeester SR, Hagen JA, et al. Clinical significance of esophageal outflow resistance imposed by a nissen fundoplication. J Am Coll Surg. 2019;229(2):210–6.CrossRef
7.
go back to reference Myers JC, Jamieson GG, Sullivan T, Dent J. Dysphagia and gastroesophageal junction resistance to flow following partial and total fundoplication. J Gastroint Surg. 2012;16(3):475–85.CrossRef Myers JC, Jamieson GG, Sullivan T, Dent J. Dysphagia and gastroesophageal junction resistance to flow following partial and total fundoplication. J Gastroint Surg. 2012;16(3):475–85.CrossRef
8.
go back to reference Gockel I, Eckardt VF, Schmitt T, Junginger T. Pseudoachalasia: a case series and analysis of the literature. Scand J Gastroenterol. 2005;40(4):378–85.CrossRef Gockel I, Eckardt VF, Schmitt T, Junginger T. Pseudoachalasia: a case series and analysis of the literature. Scand J Gastroenterol. 2005;40(4):378–85.CrossRef
9.
go back to reference Little AG, Correnti FS, Calleja IJ, et al. Effect of incomplete obstruction on feline esophageal function with a clinical correlation. Surgery. 1986;100(2):430–6. Little AG, Correnti FS, Calleja IJ, et al. Effect of incomplete obstruction on feline esophageal function with a clinical correlation. Surgery. 1986;100(2):430–6.
10.
go back to reference Schneider JH, Peters JH, Kirkman E, Bremner CG, DeMeester TR. Are the motility abnormalities of achalasia reversible? An experimental outflow obstruction in the feline model. Surgery. 1999;125(5):498–503.CrossRef Schneider JH, Peters JH, Kirkman E, Bremner CG, DeMeester TR. Are the motility abnormalities of achalasia reversible? An experimental outflow obstruction in the feline model. Surgery. 1999;125(5):498–503.CrossRef
12.
go back to reference Schwameis K, Nikolic M, Morales Castellano DG, et al. Results of magnetic sphincter augmentation for gastroesophageal reflux disease. World J Surg. 2018;42(10):3263–9.CrossRef Schwameis K, Nikolic M, Morales Castellano DG, et al. Results of magnetic sphincter augmentation for gastroesophageal reflux disease. World J Surg. 2018;42(10):3263–9.CrossRef
13.
go back to reference Ayazi S, Zheng P, Zaidi AH, et al. Magnetic sphincter augmentation and postoperative dysphagia: characterization, clinical risk factors, and management. J Gastroint Surg. 2020;24(1):39–49.CrossRef Ayazi S, Zheng P, Zaidi AH, et al. Magnetic sphincter augmentation and postoperative dysphagia: characterization, clinical risk factors, and management. J Gastroint Surg. 2020;24(1):39–49.CrossRef
14.
go back to reference Ayazi S, Zaidi AH, Zheng P, et al. Comparison of surgical payer costs and implication on the healthcare expenses between laparoscopic magnetic sphincter augmentation (MSA) and laparoscopic Nissen fundoplication (LNF) in a large healthcare system. Surg Endosc. 2019;34:2279–86.CrossRef Ayazi S, Zaidi AH, Zheng P, et al. Comparison of surgical payer costs and implication on the healthcare expenses between laparoscopic magnetic sphincter augmentation (MSA) and laparoscopic Nissen fundoplication (LNF) in a large healthcare system. Surg Endosc. 2019;34:2279–86.CrossRef
15.
go back to reference Rona KA, Reynolds J, Schwameis K, et al. Efficacy of magnetic sphincter augmentation in patients with large hiatal hernias. Surg Endosc. 2017;31(5):2096–102.CrossRef Rona KA, Reynolds J, Schwameis K, et al. Efficacy of magnetic sphincter augmentation in patients with large hiatal hernias. Surg Endosc. 2017;31(5):2096–102.CrossRef
16.
go back to reference Mombelli A, Hashim D, Cionca N. What is the impact of titanium particles and biocorrosion on implant survival and complications? A critical review. Clin Oral Implant Res. 2018;29(Suppl 18):37–533.CrossRef Mombelli A, Hashim D, Cionca N. What is the impact of titanium particles and biocorrosion on implant survival and complications? A critical review. Clin Oral Implant Res. 2018;29(Suppl 18):37–533.CrossRef
17.
go back to reference Schwameis K, Zehetner J, Rona K, et al. Post-nissen dysphagia and bloating syndrome: outcomes after conversion to toupet fundoplication. J Gastroint Surg. 2017;21(3):441–5.CrossRef Schwameis K, Zehetner J, Rona K, et al. Post-nissen dysphagia and bloating syndrome: outcomes after conversion to toupet fundoplication. J Gastroint Surg. 2017;21(3):441–5.CrossRef
18.
go back to reference Scheffer RC, Samsom M, Frakking TG, Smout AJ, Gooszen HG. Long-term effect of fundoplication on motility of the oesophagus and oesophagogastric junction. Br J Surg. 2004;91(11):1466–72.CrossRef Scheffer RC, Samsom M, Frakking TG, Smout AJ, Gooszen HG. Long-term effect of fundoplication on motility of the oesophagus and oesophagogastric junction. Br J Surg. 2004;91(11):1466–72.CrossRef
19.
go back to reference Riva CG, Siboni S, Sozzi M, Lazzari V, Asti E, Bonavina L. High-resolution manometry findings after Linx procedure for gastro-esophageal reflux disease. Neurogastroenterol Motil. 2019;32:e13750. Riva CG, Siboni S, Sozzi M, Lazzari V, Asti E, Bonavina L. High-resolution manometry findings after Linx procedure for gastro-esophageal reflux disease. Neurogastroenterol Motil. 2019;32:e13750.
Metadata
Title
Development of pseudoachalasia following magnetic sphincter augmentation (MSA) with restoration of peristalsis after endoscopic dilation
Authors
Katrin Schwameis
Shahin Ayazi
Ali H. Zaidi
Toshitaka Hoppo
Blair A. Jobe
Publication date
01-10-2020
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 5/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-020-01140-5

Other articles of this Issue 5/2020

Clinical Journal of Gastroenterology 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine